Copyright
©The Author(s) 2022.
World J Transplant. Oct 18, 2022; 12(10): 325-330
Published online Oct 18, 2022. doi: 10.5500/wjt.v12.i10.325
Published online Oct 18, 2022. doi: 10.5500/wjt.v12.i10.325
Table 1 Patients’ characteristics
| Variables at presentation | Values |
| Demographics | |
| Age, yr | 37 |
| Sex | Female |
| Race | White |
| Number of KT | 3 |
| Primary nephropathy | Focal and segmental glomerulosclerosis |
| Causes of previous KT losses | Chronic rejection |
| Time from last KT | 24 mo |
| Comorbidities | Arterial hypertension |
| Pregnancy | |
| Gestation age, wk | 20 |
| Fetal grow | Regular |
| Symptoms/signs | |
| Fever, T > 37.5 °C | Yes |
| Dyspnea | Yes |
| Anosmia | Yes |
| Myalgias | Yes |
| SARS-CoV-2 status | |
| SARS-CoV-2 swab test positive | Yes (positivity for 40 d) |
| SARS-CoV-2 vaccination | No |
| Biochemical tests | |
| At infection diagnosis | |
| Creatinine, mg/dL | 1.18 |
| WBC as × 103/mmc | 7.640 |
| Lymphocytes, cells/mmc | 1.590 |
| PTL as × 103/mmc | 202 |
| C-reactive protein, mg/L | 10.1 |
| Procalcitonin, ng/mL | 0.52 |
| Peak during infection | |
| Creatinine, mg/dL | 1.3 |
| WBC as × 103/mmc | 12.700 |
| Lymphocytes, cells/mmc | 3.400 |
| PTL as × 103/mmc | 250 |
| C-reactive protein, mg/L | 20.2 |
| Procalcitonin, ng/mL | 2.01 |
| Immunosuppression regimen | |
| Tacrolimus | Continued at unchanged doses (target levels: 7-8 μmol/L) |
| Azathioprine | Withdrawal |
| Steroids | Continued at unchanged doses (5 mg/d) |
| Outcomes | |
| Recovery from COVID-19 disease, mo | 1 |
| De novo DSA after SARS-CoV-2 infection | No |
| Rejection episode | No |
| Delivery | |
| Time of delivery, wk | 39 |
| Newborn status | Healthy, no complication |
| Time of follow-up after infection, mo | 17 |
| Renal function at last follow-up | |
| Creatinine, mg/dL | 1.09 |
- Citation: Angelico R, Framarino-dei-Malatesta ML, Iaria G. COVID-19 in a pregnant kidney transplant recipient - what we need to know: A case report. World J Transplant 2022; 12(10): 325-330
- URL: https://www.wjgnet.com/2220-3230/full/v12/i10/325.htm
- DOI: https://dx.doi.org/10.5500/wjt.v12.i10.325
